The SARS-CoV-2 virus carries almost 6.49 million deaths worldwide as of August 19, 2022.
According to Statista, the country with the highest percentage of the vaccinated population is Samoa until August 19, 2022.
Until August 29, 2022, there are 606 million active cases worldwide.
Scientists in China create a nanomaterial that attacks the spike protein of the SARS-CoV-2 coronavirus as well as variants of the virus including delta and omicron.
According to the article published in the magazine Nature Technology, A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination, In the search for alternative tools with less specificity and therefore with greater therapeutic capacity, the antimicrobial and antiviral capacity of nanomaterials has aroused special interest.
The research revealed an ultrathin two-dimensional composite nanosheet made of copper, indium, phosphorus, and sulfur (CIPS) as a new agent to combat SARS-CoV-2 infection.
According to the study, the CIPS nanosheet has shown an extremely high and selective binding capacity for the wild-type SARS-CoV-2 spike protein receptor-binding domain along with its variants, such as delta and omicron.
According to research, the United States Food and Drug Administration granted emergency use authorization for Remdesivir, Hydroxychloroquine, Paxlovid and Molnupiravir to treat COVID-19 but revoked the use of Hydroxychloroquine due to its lack of effectiveness in clinical use.
With the rapid spread of concerning variants of SARS-CoV-2, substantial limitations have been shown in the efficacy of currently approved anti-SARS-CoV-2 virus drugs, neutralizing antibodies, and vaccines.
The study demonstrates the potential of CIPS as a nanopharmaceutical for a safe and effective therapy to treat SARS-CoV-2 infection, also as a decontamination agent and surface coating material to reduce the infectivity of SARS-CoV-2.
Related Notes: